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Abstract: PURPOSE Neurodevelopmental disorders (NDD) caused by protein phosphatase 2A (PP2A)
dysfunction have mainly been associated with de novo variants in PPP2R5D and PPP2CA, and more
rarely in PPP2R1A. Here, we aimed to better understand the latter by characterizing 30 individuals with
de novo and often recurrent variants in this PP2A scaffolding A฀ subunit. METHODS Most cases were
identified through routine clinical diagnostics. Variants were biochemically characterized for phosphatase
activity and interaction with other PP2A subunits. RESULTS We describe 30 individuals with 16 different
variants in PPP2R1A, 21 of whom had variants not previously reported. The severity of developmental
delay ranged from mild learning problems to severe intellectual disability (ID) with or without epilepsy.
Common features were language delay, hypotonia, and hypermobile joints. Macrocephaly was only seen
in individuals without B55฀ subunit-binding deficit, and these patients had less severe ID and no seizures.
Biochemically more disruptive variants with impaired B55฀ but increased striatin binding were associated
with profound ID, epilepsy, corpus callosum hypoplasia, and sometimes microcephaly. CONCLUSION
We significantly expand the phenotypic spectrum of PPP2R1A-related NDD, revealing a broader clinical
presentation of the patients and that the functional consequences of the variants are more diverse than
previously reported.
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Purpose: Neurodevelopmental disorders (NDD) caused by protein
phosphatase 2A (PP2A) dysfunction have mainly been associated
with de novo variants in PPP2R5D and PPP2CA, and more rarely in
PPP2R1A. Here, we aimed to better understand the latter by
characterizing 30 individuals with de novo and often recurrent
variants in this PP2A scaffolding Aα subunit.
Methods: Most cases were identified through routine clinical
diagnostics. Variants were biochemically characterized for phos-
phatase activity and interaction with other PP2A subunits.
Results: We describe 30 individuals with 16 different variants in
PPP2R1A, 21 of whom had variants not previously reported. The severity
of developmental delay ranged from mild learning problems to severe
intellectual disability (ID) with or without epilepsy. Common features
were language delay, hypotonia, and hypermobile joints. Macrocephaly
was only seen in individuals without B55α subunit-binding deficit, and
these patients had less severe ID and no seizures. Biochemically more
disruptive variants with impaired B55α but increased striatin binding
were associated with profound ID, epilepsy, corpus callosum hypoplasia,
and sometimes microcephaly.
Conclusion: We significantly expand the phenotypic spectrum of
PPP2R1A-related NDD, revealing a broader clinical presentation of the
patients and that the functional consequences of the variants are more
diverse than previously reported.
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INTRODUCTION
Recent advances in exome sequencing have shown that de
novo pathogenic variants are the most important cause of
intellectual disability (ID) in outbred populations,1,2 and this
has led to the identification of many new genetic conditions.
Among the new causes discovered are de novo, often
recurrent, pathogenic variants in subunits of the protein
phosphatase type 2A (PP2A), the major serine/threonine
phosphatase in the human body.1–6 Since PP2A counter-
balances Ser/Thr-specific protein kinase activity, this phos-
phatase plays an essential regulatory role in cellular signaling
and physiology.7,8 PP2A phosphatases are holoenzymes,
comprising three subunits: a catalytic C, a scaffolding A and
a regulatory B-type subunit, encoded by 19 different genes in
total (2 for C, 2 for A, and 15 for B subunits).8 The B subunits
determine substrate specificity and regulation of the
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complex,9–11 and thus are the main determinants of PP2A
functions in cells and tissues.
By far the largest number of reported PP2A mutated cases
harbor de novo pathogenic variants in PPP2R5D, encoding
the regulatory B56δ subunit (25 patients).4,5,12,13 All but one
(p.P53S) of the B56δ variants that were biochemically
characterized (p.E198K, p.E200K, p.P210R, and p.W207R)
showed decreased A and C binding, suggesting a dominant-
negative mode of action.4 PPP2R5C (encoding B56γ; one case)
and PPP2R5B (encoding B56β; one case) are two additional
PP2A genes, pathogenic variants of which were associated
with ID and overgrowth.5 Although not yet biochemically
characterized, the pathogenic variants affect the very same,
highly conserved acidic loop in B56 isoforms that is
recurrently mutated in PPP2R5D-affected individuals. In
PPP2R5B, this loop supposedly serves as a substrate specifying
binding site.14 Seven patients (five variants) were reported
with de novo pathogenic variants in PPP2R1A, encoding the
scaffolding Aα subunit.4,15,16 Four of these variants (p.P179L,
p.R182W, p.R183Q, and p.R258H) also occurred somatically
in tumor tissue, and had defective binding of specific B-type
subunits, except B56δ.4,17 However, mutant Aα-B56δ com-
plexes proved catalytically impaired, potentially due to
increased binding of TIPRL1, an endogenous inhibitor of
PP2A.17 Consistent with a dominant-negative mode of action,
ectopic expression of the p.R183Q Aα variant in wild-type
(WT) PPP2R1A endometrial cancer cells increased
anchorage-independent growth and tumor formation, and
triggered hyperphosphorylation of oncogenic PP2A substrates
in GSK-3β, Akt, and mTOR/p70 S6K signaling pathways.17
Most recently, 16 individuals were reported with 15 variants
in PPP2CA, encoding the PP2A Cα subunit. Functional
characterization also revealed losses of function, consistent
with decreased PP2A-B56(δ) functionalities in most cases—
either by a dominant-negative mechanism, or by haploinsuf-
ficiency.6 Finally, a non-sense variant in BOD1 (encoding a
cellular inhibitor of PP2A-B56 complexes) was reported to
cosegregate with ID in a consanguineous family,18 and a
familial reciprocal translocation (4;6)(p16.1;q22) disrupting
PPP2R2C (encoding the PP2A-B55γ subunit) was associated
with mild ID, epilepsy, and behavioral problems.19
In the current study, we report on 30 additional cases (16
variants) with a de novo pathogenic variants in PPP2R1A. We
find that the clinical presentation of the patients is much
broader and the functional consequences of the variants are
more diverse than previously reported, expanding the
spectrum of this PP2A-related neurodevelopmental disorder.
MATERIALS AND METHODS
Ethics statement
All participants who were ascertained via research studies
gave consent to their research participation. Those individual
studies received approval from an institutional review board
(IRB) or research ethics committee. Participants who were
ascertained via clinical diagnostics procedures gave clinical
consent for testing, and their permission for inclusion in this
case collection, including photographs, was obtained using
standard forms used locally at each site. The overall case
collection study reported here did not require separate ethics
approval, based on the institutional policies of all
involved sites.
Generation of PPP2R1A mutants
The coding region of WT Aα complementary DNA (cDNA)
(NM_014225.6) was cloned into an N-terminal HA-tag
eukaryotic expression vector (pMB001) using XbaI/BamHI
sites. Mutated Aα constructs were directly generated from this
plasmid by polymerase chain reaction (PCR)–based site-
directed mutagenesis (Stratagene) with Pwo polymerase (Roche
Applied Science) and cDNA oligonucleotides (Sigma Genosys)
containing the desired point mutations (Table S1). All variants
were verified by Sanger sequencing (LGC Genomics).
Cellular PP2A binding assays
HEK293T cells (ATCC, characterized by short tandem repeat
profiling, mycoplasma-free and used at passage number <15)
were transfected with PEI transfection reagent using standard
protocol. All GFP-B-type subunit expression vectors are
previously described.4,17,20 Forty-eight hours post-transfection,
cells were rinsed with PBS, lysed in 150 μl NET buffer (50mM
Tris.HCl pH 7.4, 150mM NaCl, 15 mM EDTA, and 1%
Nonidet P-40) containing protease and phosphatase inhibi-
tor cocktail (Roche Applied Science) and centrifuged for
15 minutes at 13,000g. For binding assays with GFP-STRN3,
no phosphatase inhibitors were added. If the experiment
required measuring phosphatase activity, TBS was used
instead of PBS and phosphatase inhibitors were omitted.
For pulldown experiments, lysates were incubated at 4 °C for
1 hour with 800 µl NENT100 buffer (20 mM Tris.HCl pH 7.4,
1 mM EDTA, 0.1% Nonidet P-40, 25% glycerol, 100mM
NaCl) containing 1 mg/ml bovine serum albumin, and 20 μl
anti-HA-Agarose beads (Sigma-Aldrich, for HA pull down), or
20 μl GFP-trap-A beads (ChromoTek, for GFP trapping).
Beads were washed three times with 1 ml NENT300 (contain-
ing 300mM NaCl), and two times with 1 ml NENT150
(containing 150mM NaCl). Bound proteins were eluted in 2×
NuPage sample buffer (Invitrogen) and boiled for subsequent
analysis by sodium dodecyl sulfate polyacrylamide gel
electrophoresis (SDS-PAGE) on 4–12% (w/v) Bis-Tris gels
(BioRad) and western blotting. Membranes were blocked in
5% milk in TBS/0.1% Tween-20 for 1 hour at room
temperature and incubated with the primary antibody over-
night at 4 °C. Primary mouse monoclonal antibodies were
anti-HA (clone HA-7, Sigma-Aldrich), anti-GFP (clone 9F9.
F9, Abcam), anti-PP2A-C subunit (clone F2.6A10, generously
supplied by Dr. S. Dilworth, Middlesex University, London,
UK). After washing in TBS/0.1% Tween-20, membranes were
incubated with horseradish peroxidase–conjugated secondary
antibodies (Dako) and developed using Western Bright ECL
(Advansta) on the ImageQuant LAS4000 scanner (GE
Healthcare). All densitometric quantifications were done with
Image Studio Lite software (version 5.2).
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PP2A activity assays
After HA pulldown, beads were washed with 50 mM Tris-HCl
pH 8.0 supplemented with 1 mM DTT, and resuspended in
75 µl of the same buffer. Assays were performed with 35 µl of
this phosphatase suspension, and 10 µl of 2mM R-K-(p)T-I-
R-R phosphopeptide or pRb phosphopeptide (I-N-G-S-P-R-
(p)T-P-R-R-G-Q-N-R) for 10 and 20 minutes at 30 °C (in the
linear range of the assay). Released phosphate was determined
by addition of Biomol®Green (#BML-AK111-0250, Enzo) and
absorbance measurement at 620 nm in a multichannel
spectrophotometer. Specific phosphatase activity was
obtained by correcting the measured absorbance for the
input of HA-tagged Aα as determined and quantified by
immunoblotting.
Functional studies with p.Ser152Phe variant
Mouse experiments were performed according to protocols
approved by University of Tours and INSERM (Project
01456.03, French Ministry of Research). Hippocampal neu-
rons from embryonic day 17 embryos were prepared and
plated at a density of 450 cells/mm2 as described.21 Mature
primary hippocampal mouse neurons (13 days in vitro) were
transfected with pEGFP (vector only), Aα WT or Aα
p.Ser152Phe-GFP fusion expression vector (three independent
transfections). Forty-eight hours later, confocal microscopy
(Leica SP8) images of fixed neurons were analyzed, and the
number of dendritic spines in 10-µm sections determined
(pEGFP: 134 sections, 19 cells; Aα-GFP: 190 sections, 18 cells;
Aα Ser152Phe-GFP: 231 sections, 18 cells).
Statistics
Statistical analysis of biochemical data was assessed with one-
sample Student t-tests using GraphPad Prism 8.4.2 software—
data were compared with WT values that were set at 100% in
each experimental replicate. At least three replicates were
analyzed for each measurement; p values below 0.05 were
considered significant (*p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001;
****p ≤ 0.0001). Statistical comparative analysis of the
counted number of spines was performed with GraphPad
Prism 6 software and a Kruskal–Wallis test followed by Dunn
multiple comparisons test.
RESULTS
Mutational spectrum is diverse and suggests impaired
PPP2R1A subunit functioning
In total, 16 different de novo variants (of which 6 were
recurrent) were identified in 30 individuals, in most cases
through routine clinical diagnostic procedures, including
exome sequencing. Individuals 5, 7, 10, 17, 19, and 25 were
identified through the Deciphering Developmental Disorders
(DDD) Study.3 Individual 23 was identified via a research
study that provided trio exome sequencing. All variants
resulted in nonidentical, single amino acid substitutions
(Fig. 1a). Four variants, p.Pro179Leu (1 case), p.Arg182Trp
(3 cases), p.Ser219Leu (3 cases), and p.Arg258His (2 cases)
had previously been reported;4,16 hence, 12 variants were
novel.
Structurally, the Aα subunit consists of 15 HEAT repeats
(HRs; Huntingtin - Elongation factor - A subunit - TOR),
organized into a horseshoe-shaped molecule.22 Each HR is
constituted of two antiparallel helices that are connected by an
intrahelical loop (Fig. 1b, c). These intrahelical loops form a
continuous ridge at one side of the molecule that provides the
direct binding contacts with other PP2A subunits: in
particular, the loops from HR1 to HR7 provide the contacts
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Fig. 1 Schematic overview of neurodevelopmental delay-associated variants in the PP2A scaffolding Aα subunit. (a) De novo pathogenic
variants in PPP2R1A identified in individuals with intellectual disability and (neuro)developmental delay are shown with respect to their exonic and Aα
protein localization respectively, with exon notation by Roman numbering (I–XV) and indications of the 15 HEAT repeats (HRs) within the protein structure.
(b) Detailed amino acid sequence of the affected HRs (HR1, HR4, HR5, HR6, and HR7), with the intrarepeat loop indicated in purple, and the affected amino
acids underlined and in bold. (c) More schematic representation of the antiparallel helical structures of the HRs with the B subunit binding intrarepeat loops.
The red crosses indicate the approximate locations of the mutated amino acids found in the affected individuals.
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from HR 11 to HR15 bind to the catalytic C subunit
(Fig. 1a).28 Interestingly, seven of the novel variants,
p.Thr178Asn, p.Thr178Ser, p.Met180Val, p.Met180Thr,
p.Met180Lys, p.Met180Arg, and p.Arg183Trp, reside imme-
diately adjacent to or affect the same amino acid as the
previously reported Aα HR5 loop variants (p.Pro179Leu,4
p.Arg182Trp,4 and p.Arg183Gln15) (Fig. 1a–c). The novel
variant p.Val220Met resides immediately adjacent to the
reported p.Ser219Leu16 in the loop of HR6, and another novel
variant, p.Arg258Ser, affects the same amino acid as the
previously reported one (p.Arg258His4) in the loop of HR7.
The novel p.Phe141Ile variant resides in the intrarepeat loop
of HR4 (Fig. 1a–c), a loop not previously reported to be
affected. Thus, the large majority of Aα variants affect amino
acids predicted to be involved in B-type subunit binding and
reside in the intrarepeat loops of HR4, HR5, HR6, and HR7.
In contrast, the novel p.Ile32Met and p.Ser152Phe variants
reside in one of both helical structures of HR1 or HR4,
suggesting they might not be directly involved in B-type
subunit binding (Fig. 1a–c).
Clinical spectrum associated with PPP2R1A variants
The core clinical information on all 30 PPP2R1A-affected
patients is summarized in Table 1; more details can be found
in Table S2. Facial features of 12 individuals are displayed in
Fig. S1. Individuals were aged 10 months to 27 years, and all
except one had developmental delay of a severity that was
certainly or likely within the ID range. The one exceptional
individual, with a de novo p.Ser152Phe variant (individual 3,
Table 1), had an autism spectrum disorder (ASD) and a full
scale IQ of 86. In the others with ID, most were moderate to
severe, but two could have mild ID only. The presence of
epilepsy or brain malformations (corpus callosum hypoplasia,
ventriculomegaly, and/or periventricular leukomalacia) was
found in individuals with moderate to severe ID. Table 2
provides an overview of the main phenotypic features and
their prevalence. A subgroup of 11 individuals had macro-
cephaly; the rest either normocephaly or microcephaly (n= 7)
(Table 2). Uniform features were neurodevelopmental delay
with prolonged hypotonia and language delay. The subgroup
with macrocephaly did not have epilepsy, and all cases with
ptosis (n= 5) and hearing loss or microtia (n= 3) belonged to
this group (Table 2). The facial features were variable, from
fairly normal to clearly dysmorphic (Fig. S1). Frontal bossing
or a tall forehead was typical for the macrocephalic group
(individuals 2, 9, 13, 14, Fig. S1), and these features could also
be reminiscent of Sotos syndrome (individual 2) or Weaver
syndrome (individual 14), but body lengths were usually
normal (Table S2). Of note, digital malpositioning was seen
in the severely p.Arg182Trp affected cases (Fig. S1). Affection
of brain function and morphology is the main clinical
problem caused by PPP2R1A dysfunction, but as a clue to
diagnosis, mild facial dysmorphism (e.g., frontal bossing, tall
forehead, downslanting or upslanting palpebral fissures) can
be seen in some (Table 1, Fig. S1). As mentioned, head
circumference was either normal (38%), macrocephalic (38%)
or microcephalic (24%), representing an unusual distribution
across the full range. Head size did not show a clear
correlation with the degree of ID or the presence of epilepsy,
but the macrocephalic individuals mostly had moderate ID
(8/11). Malformations are not common in this cohort, and the
persistent ductus arteriosus in 3/30 individuals could be a
random association—or a mild susceptibility. It is also
noteworthy that no individuals, except one, had been
diagnosed with a malignancy: individual 22 was operated
for a paratesticular lipoblastoma at age 1 year. Tumor nodules
were composed of mature adipocytes and vacuolated
lipoblasts showing varying degrees of differentiation.
To correlate clinical with biochemical findings, a crude
clinical severity score was calculated based on degree of
developmental delay (1–4 points), epilepsy (+1), macro/
microcephaly (+1), malformations (+1), corpus callosum
hypoplasia (+1), short stature (+1), and other major findings
(+1) for a maximum score of 10 (Tables 1, S3). There was a
correlation between variant type and severity, e.g., individuals
with p.Met180Thr and p.Met180Val usually had moderate ID
and all individuals with p.Arg182Trp had severe ID, with some
degree of variation for a given variant (Table 1).
PPP2R1A variants show altered PP2A B-type subunit
binding in a variant-specific manner
We assessed binding of 13 Aα variants (p.Phe141Leu,
p.Ser152Phe, p.Thr178Asn, p.Pro179Leu, p.Met180Thr,
p.Met180Val, p.Met180Lys, p.Arg182Trp, p.Arg183Trp,
p.Ser219Leu, p.Val220Met, p.Arg258His, and p.Arg258Ser)
to at least one representative of the regulatory B/B55, B’/B56,
B”/PR72 and B”’/striatin subunit classes. To this end, N-
terminally GFP-tagged B55α (encoded by PPP2R2A), B56α to
ε (encoded by PPP2R5A-R5E), B”/PR72 (encoded by
PPP2R3A), and B”’/STRN3 (encoded by PPP2R6B) (Figs. 2,
S2–S9) were coexpressed with HA-tagged WT or mutant Aα.
The retrieved Aα proteins in GFP traps were subsequently
visualized by anti-HA immunoblotting. As previously reported,4
we confirmed near complete loss of binding of the B55α subunit
to the p.Pro179Leu, p.Arg182Trp, and p.Arg258His variants
(Figs. 2a, S2), while the binding behavior of not previously
biochemically tested variants appeared in part identical
(for variants p.Arg183Trp, p.Ser219Leu, p.Val220Met, and
p.Arg258Ser), and in part completely opposite to this observa-
tion. Binding of B55α was indeed fully retained in p.Phe141Ile,
p.Ser152Phe, p.Thr178Asn, p.Met180Thr, and p.Met180Val,
and was 50% decreased in p.Met180Lys (Figs. 2a, S2). This
binding behavior was consistent with results from PP2A activity
assays using a PP2A-B55 holoenzyme-specific substrate, derived
from the pRb protein.29 In these assays, significant PP2A
activity was only found in the variants that still significantly
bound B55α (Fig. 2b).
We next performed binding assays with STRN3, a representa-
tive member of the PP2A B”’ subunit family. Interestingly,
no significant differences in binding compared with WT Aα
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were observed with Aα variants exhibiting retained B55α binding
(i.e., p.Phe141Ile, p.Ser152Phe, p.Thr178Asn, p.Met180Thr,
p.Met180Val), while a significant (or trend toward) gain of
binding of STRN3 was observed for the variants with lost or
decreased B55α binding (p.Met180Lys, p.Arg182Trp, p.
Arg183Trp,
p.Ser219Leu, p.Val220Met, p.Arg258His, and p.Arg258Ser), with
p.Pro179Leu being the only exception (Figs. 2c, S3).
Within the B56 family of B subunits, isoform-specific
binding dysfunctions were observed for different Aα variants.
Consistent with previous observations,4 binding of B56δ was
retained in all variants (Figs. 2d, S4). For B56α, loss of or
significantly decreased binding was seen to Aα variants
p.Phe141Ile, p.Thr178Asn, p.Pro179Leu, p.Met180Lys/Thr/
Val, p.Arg182Trp, and p.Arg183Trp, while binding was
retained in all other Aα variants tested (Figs. 2e, S5). For
B56β, the same pattern of binding deficiencies was observed, in
addition to decreased binding to p.Ser219Leu and p.Val220Met
(Figs. 2f, S6). B56γ1 and B56ε showed a near identical pattern of
binding deficiencies, with significantly impaired or lost binding
to all Aα variants, except p.Ser152Phe, p.Val220Met, Arg258His
and p.Arg258Ser (Figs. 2g, h, S7–S8).
For the B”/PR72 subunit, another unique binding deficiency
pattern was found, with lost or significantly decreased binding
to Aα variants p.Phe141Ile, p.Met180Thr/Val, p.Arg182Trp,
p.Arg183Trp, and p.Arg258His/Ser (Figs. 2i, S9).
Some PPP2R1A variants show altered C subunit binding and
impaired overall PP2A activity
We next assessed binding of HA-tagged Aα variants to
endogenous PP2A C subunit (Fig. 3a, b). Whereas, compared
with WT Aα, no obvious impairment of C subunit binding
could be observed for Aα variants p.Ser152Phe, p.Thr178Asn,
and p.Met180Lys/Thr/Val, C subunit binding was significantly
affected by about 50% or more for p.Phe141Ile, p.Pro179Leu,
p.Arg182Trp, p.Arg183Trp, p.Ser219Leu, p.Val220Met, and
p.Arg258His/Ser (Fig. 3a, b). PP2A activity measurements
using a nonspecific artificial phosphopeptide (i.e., one that is
equally well dephosphorylated by all PP2A holoenzymes),
showed significantly decreased activities by 48–70% for p.
Thr178Asn, p.Pro179Leu, p.Arg182Trp, and p.Arg258His/Ser
variants (Fig. 3c).
Decreased number of dendritic spines in hippocampal
neurons expressing p.Ser152Phe
So far, only the p.Ser152Phe variant did not show any functional
impairments in our biochemical assays. To provide further insights
into its potential pathogenicity, we expressed it as a GFP fusion
protein in mature primary hippocampal neurons. Compared with
GFP or WT Aα-GFP expressing neurons, a significantly decreased
number of dendritic spines was found in these neurons (Fig. 3d, e),
suggesting p.Ser152Phe may indeed be pathogenic. Of note, the
PP2A Aα subunit is part of the postsynaptic density,30 and PP2A
Table 1 Overview of main phenotypic features with severity score.
Individual 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
Severity
scorea
4 5 1 4 6 9 5 4 6 5 4 4 4 4 5
Age 11y 4y 18y 18y 12y 4y 3y 9mo 6y 2y 23y 2y 27y 20y 1y 4mo 10 mo































p. I32M F141I S152F T178S T178N P179L M180T M180T M180T M180T M180T M180V M180V M180V M180K
Inheritance dn dn dn dn dn dn dn dn dn dn dn dn ? dn dn
Birth size N N N N N N N N N N N N N
Height N N N N N −3 SD N N N N N N −2.6 SD N
Head
circumference
N macroC N +5.1 SD +2 SD microC +2 SD macroC +3.4 SD +2.5 SD +3.9 SD +2 SD +3 SD +5.2 SD N
DD/ID ID++ ID+++ IQ 86 ID++ ID+++ ID+++ ID+++ ID++ ID++ ID++ ID++ ID++ ID++ DD ID+++
Language
delay
++ ++ + + +++ +++ ++ ? + + + + ? ?
Age of
walking










Hypotonia yes yes no yes yes yes yes yes +++ ++ +++ ++ ++ yes +++
Feeding
problems
no reflux no no yes TPN yes mild yes no yes no no
Epilepsy ++ N no no no ++ no no no no no no no yes
Corpus
callosum
































N N N N N N
Extremities/
spine





Heart N N N PDA PDA N N
athe severity score was calculated based on crude judgement of clinical severity: DD = 1 + 1-3 for ID (i.e. max=4), malformations = 1, corpus callosum hypoplasia/agen-
esis = 1, epilepsy = 1, short stature/SGA = 1, macro- or microcephaly = 1, other major findings (unspecified, based on overall impression of clinical severity) = 1. Lan-
guage delay was scored from + to +++ when possible: + = mild, ++ = moderate, +++ = severe, based on the age of the individual and the clinical information
provided. The scoring is crude but indicative. A “?” indicates “too early to know”. Similar scoring (+ mild, ++ moderate, +++ severe) was done of ID and hypotonia,
when possible, otherwise “yes/no” or “ID” was noted.
Abbreviations: ADHD attention deficit-hyperactivity disorder, ASD autism spectrum disorder, DD developmental delay, dn de novo, hyperm. hypermobility, ID intellectual
disability, macroC macrocephaly, microC microcephaly, mo months, N normal, OCD obsessive compulsive disorder, PDA persistent ductus arteriosus, PEG percutaneous
endoscopic gastrotomy, PFO persistent foramen ovale, PVLM periventricular leukomalacia, SGA small for gestational age, TPN total parenteral nutrition, y years.
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function could have importance for regulating dendritic spine
number during neuronal development.
DISCUSSION
Although incompletely understood, PP2A phosphatases play
important roles in mammalian brain development and
function,8,31,32 e.g., in regulating signaling33–35 and preventing
degeneration in neurons.36,37 In 2015, PP2A dysfunction was
reported as a new cause of syndromic intellectual disability
and (neuro)developmental delay, involving de novo loss-of-
function pathogenic variants in PPP2R1A and PPP2R5D,4 and
likely also in PPP2R5C and PPP2R5B, although the latter has
not yet been functionally confirmed.5 Later, the set of affected
genes was extended to PPP2CA,6 and the overlapping
syndromes, all characterized by severe PP2A dysfunction,
were proposed to be called “PP2A-related neurodevelopmental
disorders.” Here, we significantly expand the spectrum of
PPP2R1A variants and phenotypes through analysis of 30
additional patients. While all previously reported PPP2R1A-
affected cases represented individuals with severe ID, often
associated with epilepsy and microcephaly, more diversity is
seen in the current cohort, with several cases being
phenotypically milder, and at least one without ID but with
only learning problems and autistic features. Interestingly, this
wider phenotypic spectrum correlates well with the more
diverse biochemical dysfunctions found in this broader cohort,
with the most pronounced difference seen in the binding
behavior of Aα variants to the B-type subunits, B55α and
STRN3. Indeed, patients with less severe ID, no seizures, and
sometimes macrocephaly typically showed normal B55α and
STRN3 binding, while patients with more severe ID, seizures,
and sometimes microcephaly typically lost B55α binding and
showed increased STRN3 binding. Notably, these functionally
more disruptive variants were also found in the Catalogue Of
Somatic Mutations In Cancer (COSMIC), or were affected in
the same amino acid as cancer-associated PPP2R1A variants
(Table S3). Reported functional studies of these cancer-
associated Aα variants confirmed their increased oncogenic
potential in cancer cell growth, migration, and drug
resistance.17,38–40 Only for p.Pro179Leu was the inverse
correlation between loss of B55α binding and gain of STRN3
binding not found, which could be explained by the broader
structural disruptive nature of this variant, as shown before for
the cancer-associated p.Pro179Arg variant.39 It is noteworthy
that one individual (22, p.Ser219Leu, present in COSMIC) was
affected at young age by a relatively rare tumor (paratesticular
lipoblastoma). However, since this is the first PPP2R1A case
reported with a malignancy, it is unclear whether this is mainly
coincidental or part of the clinical phenotype of the more
severely affected PPP2R1A subgroup.
With respect to B56 isoform binding, all new ID-associated
Aα variants, without exception, retained binding to B56δ, as
Table 1 (continued) Overview of main phenotypic features with severity score.
Individual 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30
Severity
scorea
4 8 6 9 8 5 7 2 5 7 5 5 7 5 4
Age 9y 6y 4y 3y 2y 20y 2y 4mo 7y 4y 7y 3y 4y 4y 1y 6mo 1y
1mo































p. M180R R182W R182W R182W R183W S219L S219L S219L V220M V220M V220M V220M R258H R258H R258S
Inheritance dn dn dn dn dn dn dn dn dn dn dn dn dn dn dn
Birth size SGA N N SGA N N N N SGA SGA N SGA N N
Height N N N N -2.5 SD N N N N N N N N N
Head
circumference
-2.4 SD N N N N -2 SD N N −2.5 SD N N −3.5 SD −3 SD −3.1
SD
DD/ID ID+ ID+++ ID+++ ID+++ ID+++ ID++ ID++ DD ID ID++ ID+ ID++ ID++ DD DD
Language
delay
+ +++ +++ +++ ++ + ++ + +++ ++ ++ +++ + ?
Age of
walking








Hypotonia yes yes +++ +++ yes yes yes yes yes yes yes no yes no
Feeding
problems
mild PEG PEG no initial no no no yes no no no
Epilepsy no + no +++ +++ ++ ++ no +++ +++ no no + no no
Corpus
callosum
N agenesis hypoplastic agenesis hypo-
plastic











































coarse face long face plagio-
cephaly
N
Ears/hearing N N N N N N N N N N N N
Extremities/
spine
hyperm. scoliosis scoliosis N hyperm. hyperm.
Heart N PDA, PFO N N N N
athe severity score was calculated based on crude judgement of clinical severity: DD = 1 + 1-3 for ID (i.e. max=4), malformations = 1, corpus callosum hypoplasia/agen-
esis = 1, epilepsy = 1, short stature/SGA = 1, macro- or microcephaly = 1, other major findings (unspecified, based on overall impression of clinical severity) = 1. Lan-
guage delay was scored from + to +++ when possible: + = mild, ++ = moderate, +++ = severe, based on the age of the individual and the clinical information
provided. The scoring is crude but indicative. A “?” indicates “too early to know”. Similar scoring (+ mild, ++ moderate, +++ severe) was done of ID and hypotonia,
when possible, otherwise “yes/no” or “ID” was noted.
Abbreviations: ADHD attention deficit-hyperactivity disorder, ASD autism spectrum disorder, DD developmental delay, dn de novo, hyperm. hypermobility, ID intellectual
disability, macroC macrocephaly, microC microcephaly, mo months, N normal, OCD obsessive compulsive disorder, PDA persistent ductus arteriosus, PEG percutaneous
endoscopic gastrotomy, PFO persistent foramen ovale, PVLM periventricular leukomalacia, SGA small for gestational age, TPN total parenteral nutrition, y years.
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reported previously4 (Table S3). Binding to all other B56
isoforms was significantly decreased or completely lost for Aα
variants affected in the intrarepeat loops of HR4 and HR5,
while Aα variants affected in the loop of HR7 fully retained
binding. Aα variants affected in the loop of HR6 showed a
more variable B56 isoform-specific pattern of binding
deficiencies. In contrast, B”/PR72 binding was significantly
decreased or lost to Aα variants affected in the intrarepeat
loops of HR4 and HR7, while it was completely retained with
Aα variants affected in the loop of HR6. A more variable B”/
PR72 binding deficiency pattern was found with Aα variants
affected in the loop of HR5. Thus, the binding requirements
of different B-type subunit families to each of the Aα HEAT
repeats 4–7 appeared in part overlapping, in part clearly
different (Fig. S10).
Structural data from different PP2A trimers, each harboring
a single representative of the four PP2A B-type subunit classes,
further underscore the presumed functional importance of
most affected Aα residues in B-type subunit binding. Indeed,
structural data from crystallized Aα-B56γ1-C trimers high-
lighted the importance of Aα Trp140 and Phe141 residues in
making multiple van der Waals interactions with hydrophobic
residues in B56γ1,23,24 while Arg183 donates a pair of charge-
stabilized hydrogen bonds to Glu214 of B56γ1.23 Other Aα
residues involved in direct contacts with B56γ1 are Asp177,
Thr178, Pro179, and Met180.24 A smaller contact area between
Aα and B56γ1 involved the ridge of Aα HR7, where Trp257
hydrogen bonds to a main chain carbonyl group of B56γ1.23
Six Aα residues make direct contacts with the B55α subunit:
Trp140, Phe141, Thr178, Arg183, Asp218, and Trp257,25 while
Trp140, Met180, Arg183, and Arg258 are part of an extensive
binding surface between Aα and the B”/PR70 subunit.26 In
contrast, truncation of HR1–HR3 of Aα sufficed to abolish
interaction with the coiled coil domain of the B”’/striatins,
suggesting that Aα-striatin contacts are largely mediated by
HR1 to HR3.27 However, despite the availability of these
structural data, the pattern of specific B-type subunit-binding
defects to the various Aα variants, experimentally determined
here, appeared largely, if not completely, unpredictable. For
instance, despite the fact that Phe141, Thr178, and Arg183
were reported to make direct contacts with B55α, the p.
Phe141Ile and p.Thr178Asn variants clearly fully retained
B55α binding, while p.Arg183Trp completely lost B55α
binding. Likewise, while Met180 was reported to be part of
the binding surface with B”/PR70, only Met180Thr/Val
substitutions significantly affected B”/PR72 binding, while p.
Met180Lys bound normally. This testifies to complex regula-
tion and precise fine-tuning of amino acid contacts between
Aα and the diverse B-type subunits.
In accordance with previous studies,4,17 eight of the tested
ID-associated Aα variants bound significantly less to the
PP2A catalytic subunit, despite the C subunit-binding domain
residing in HR10-HR15.28 However, this decrease in C
binding did not seem to correlate well with decreased Aα-
associated PP2A activity, which was only observed for three of
these affected variants (p.Pro179Leu and p.Arg258His/Ser).
Thus, in the latter cases, a dominant-negative mechanism
could be in place, as these Aα variants still form trimeric
complexes with respectively, B56δ and PR72 (for p.Pro179-
Leu), and all B56 isoforms (for p.Arg258His/Ser), but show
impaired phosphatase activity. Conversely, p.Thr178Asn
showed decreased associated PP2A activity, while having
normal C subunit binding, perhaps hinting at a different
substrate specificity for this variant.
Finally, of all PPP2R1A variants functionally examined here,
only p.Ser152Phe appeared biochemically normal in our
assays (Table S3). This is both in concordance with the mild
phenotype of the affected individual (individual 3), as well as
with the localization of Ser152 outside of the intrahelical loop,
but within one of the helices, of HR4 (Fig. 1). Nevertheless,
neurons expressing this variant presented with fewer dendritic
spines, testifying of an altered functionality, compared with
WT Aα (Fig. 3d, e). These findings thus expand the PPP2R1A
phenotype to include ASD without ID.
In summary, the extended number of de novo PPP2R1A
variants reported here revealed a wider phenotypic spectrum
than previously anticipated, which correlated well with the more
diverse biochemical dysfunctions found. Apart from
p.Ser152Phe, all functionally tested variants were impaired in
binding to a specific set of B-type subunits, except for binding to
B56δ (which was normal in all cases), and for binding to STRN3
(which was increased in some cases). Combined with
significantly decreased PP2A activity found in a number of
variants, these binding deficiencies result in a complicated
pattern of PP2A dysfunctions, which may affect specific trimeric
holoenzymes both by dominant-negative as well as haploinsuf-
ficiency mechanisms. One subgroup of variants (p.Phe141Ile,
Table 2 Summary of main phenotypic features.
Phenotypic feature All % of reported With MCa
Language delay 22/22 100% 8/8
Developmental delay 29/30 97% 11/11
Hypotonia 25/27 93% 11/11
Behavior problems 11/17 65% 6/6
Frontal bossing/long face 15/24 63% 8/8
Hypermobile joints 11/19 58% 4/6
CC hypoplasia/agenesis 14/25 56% 1/8
Thin upper lip 10/22 46% 2/8
Epilepsy 10/26 38% 0/10
Macrocephaly 11/29 38%
Ptosis 5/20 25% 5/9
High palate 5/20 25% 3/8
Tented upper lip 5/20 25% 2/8
Microcephaly 7/29 24%
Hearing loss 3/20 15% 3/10
Microtia/ear hypoplasia 3/20 15% 3/10
Short stature 3/27 11% 1/10
CC corpus callosum.
aMC=macrocephaly group (F141I, T178S, T178N, M180T, M180V).
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p.Thr178Asn, p.Met180Val/Thr/Lys; absent from COSMIC)
presented overall with a milder biochemical and clinical
phenotype, while another subgroup (p.Pro179Arg, p.Arg182Trp,
p.Arg183Trp, p.Ser291Leu, p.Val220Met, p.Arg258His/Ser; all
with affected amino acids present in COSMIC) was overall more
severely affected, both biochemically and phenotypically. These
findings have major consequences for diagnosis, clinical
management, and follow-up of PPP2R1A-affected patients,
and provide additional rationales for functional follow-up
studies in cell and mouse models.
SUPPLEMENTARY INFORMATION
The online version of this article (https://doi.org/10.1038/s41436-
020-00981-2) contains supplementary material, which is available
to authorized users.
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Fig. 2 Binding of PP2A Aα variants to representative members of all PP2A regulatory B subunit families. (a, c–i). GFP-tagged B55α (a), B”’/STRN3
(c), B56δ (d), B56α (e), B56β (f), B56γ1 (g), B56ε (h), B”/PR72 (i) or GFP alone (as a control) was coexpressed with HA-tagged wild-type (WT) or variant Aα
proteins in HEK293T cells. The presence of Aα variants was subsequently assessed in GFP traps by anti-HA immunoblotting. Representative blots can be
found in Figs. S2–S9. Shown is the average value +/- SD of the ratios of the quantified anti-HA signal versus the quantified anti-GFP signal for a given Aα
variant, relative to those of WT Aα (set at 100% in each experiment, dotted line), as determined in at least three independent binding experiments (n ≥ 3). A
one-sample t-test (compared with 100%) was used to assess statistical significance (*p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001). (b) PP2A activity
measurements on a PP2A-B55-specific phosphopeptide. HA-tagged WT and variant Aα proteins were purified from transfected HEK293T cells by HA
pulldown, and absolute PP2A activity was determined on the I-N-G-S-P-R-(p)T-P-R-R-G-Q-N-R phosphopeptide substrate using Biomol®Green. Specific PP2A
activities were calculated by correcting the measured activities for actual Aα inputs, determined by anti-HA immunoblotting. Results represent the average
specific activity +/- SD for a given Aα variant, relative to the specific activity of WT Aα (set at 100% in each experiment), as determined in at least three
independent experiments (n ≥ 3). A one-sample t-test (compared with 100%) was used to assess statistical significance (*p < 0.05; **p < 0.01; ****p <
0.0001).
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Flanders). Patient 23 was ascertained in the Duke Genome
Sequencing Clinic as participant in a research study (Duke
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Fig. 3 Binding of PP2A Aα variants to the C subunit and Aα variant-associated activity. (a) C subunit binding. HA-tagged wild-type (WT) Aα and Aα
variants were purified from transfected HEK293T cells by HA pulldown, and the presence of endogenous C subunit in the complexes determined by anti-A
immunoblotting. (b) Quantified C subunit binding values. Results represent the average value +/- SD of the ratios of the quantified anti-C signal versus the
quantified anti-HA signal for a given Aα variant, relative to those of WT Aα (set at 100% in each experiment), as determined in at least three independent
experiments (n ≥ 3). A one-sample t-test (compare to 100%) was used to assess statistical significance (*p < 0.05; **p < 0.01; ***p < 0.001; ****p <
0.0001). (c) Associated phosphatase activity of Aα variants, measured on a nonspecific PP2A substrate. HA-tagged WT Aα and Aα variants were purified
from transfected HEK293T cells by HA pulldown, and PP2A activity was determined on the artificial, holoenzyme nonspecific K-R-(p)T-I-R-R phosphopeptide
substrate using Biomol®Green. Specific PP2A activities were calculated by correcting the measured activities for actual Aα inputs, determined by anti-HA
immunoblotting. Results represent the average specific activity +/- SD for a given Aα variant, relative to the specific activity of WT Aα (set at 100% in each
experiment), as determined in at least three independent experiments (n ≥ 3). A one-sample t-test (compared with 100%) was used to assess statistical
significance (*p < 0.05; **p < 0.01; ***p < 0.001). (d, e) Dendritic spine analysis in hippocampal neurons expressing Aα variant p.Ser152Phe. Confocal
images of fixed primary hippocampal neurons (DIV 13) 48 hours after transfection with pEGFP (negative control), WT Aα–GFP or Aα Ser152Phe-GFP (d).
Quantification of the number of dendritic spines for the transiently expressed GFP, WT Aα, and Aα variant p.Ser152Phe (e). For each neuron analyzed, the
number of spines in 10-μm sections was counted: pEGFP (3 transfections; 19 cells, 134 sections), Aα–GFP (3 transfections; 18 cells, 190 sections), Aα
Ser152Phe-GFP (3 transfections; 18 cells, 231 sections). Each plot represents the mean value of sections analyzed in one neuron. Statistical comparative
analysis was performed using a nonparametric Kruskal–Wallis test followed by Dunn multiple comparisons tests. ****p < 0.0001, ns not significant.
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